News from NORD

More Than 100 Patient Organizations Join NORD in Supporting the RARE Act


 

NORD has sent a letter to Congress, signed by more than 100 patient advocacy organizations, in support of the Rare disease Advancement, Research, and Education Act of 2018 (H.R.5115) or the “RARE Act of 2018.” Read NORD’s letter to see how this proposed legislation would help patients and families affected by rare diseases, medical researchers, and clinicians seeking to provide optimal care for their patients.

Recommended Reading

How Accurately Do Current Criteria Identify CBD and PSP?
MDedge Neurology
FDA approves Epidiolex for Lennox-Gastaut syndrome and Dravet syndrome
MDedge Neurology
FDA Approves a Cannabinoid Medicine for Two Forms of Epilepsy
MDedge Neurology
Patisiran May Reduce Neuropathy in Patients With hATTR Amyloidosis
MDedge Neurology
FDA Efforts to Advance Development of Gene Therapies
MDedge Neurology
Risk of ALS May Increase With Greater Exposure to Diesel Exhaust
MDedge Neurology
Childhood Neuromuscular Disease as a Metaphor for the Scientific Advances in Child Neurology of the Last Quarter Century
MDedge Neurology
Register Now for NORD’s Rare Impact Awards Celebration
MDedge Neurology
2018 Marks 35th Anniversary of NORD and the Orphan Drug Act
MDedge Neurology
RFPs Available for the Study of Three Rare Diseases
MDedge Neurology